Candriam S.C.A. Avadel Pharmaceuticals PLC Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 22, 2021	SELL	$5.03 - $7.95 $427,550 - $675,750	-85,000 Closed	0 $0
Q2 2020 Jul 23, 2020	BUY	$7.25 - $11.75 $616,250 - $998,750	85,000 New	85,000 $687,000
Q1 2019 May 02, 2019	SELL	$1.44 - $3.29 $89,280 - $203,980	-62,000 Closed	0 $0
Q4 2017 Feb 07, 2018	SELL	$8.03 - $11.25 $393,469 - $551,250	-49,000 Reduced 44.14%	62,000 $508,000
Q3 2017 Nov 03, 2017	BUY	$8.35 - $10.5 $926,850 - $1.17 Million	111,000	111,000 $1.17 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.